AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05776706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AR-based navigation
Description: The surgeon will perform all surgical planning and operations with reference to the existing navigation. In this process, the errors of the existing navigation and the newly developed navigation are measured and compared in 3D at several points, and the points are as follows.~1. Fiducial markers~2. Nasion~3. Tumor's margin (anterior, posterior, superior, inferior)
Study NCT06488599 — intervention group
Intervention type: RADIATION
Intervention: Peri-apical radiographs on the implants
Description: Peri-apical radiographs on the implants supporting the prosthesis
Study NCT05822440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07817883
Description: Single oral dose (period 1) or co-administered with itraconazole (period 2)
Study NCT05822440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Interacting drug which will be given for 7 days in period 2
Study NCT06567015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-241
Description: Film-coated tablet~Route of administration: Oral
Study NCT06094140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure.
Study NCT06094140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 intravenously on day 1
Study NCT06094140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150mg/m2 intravenously on day 1
Study NCT06094140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate (leucovorin)
Description: 50mg as an intravenous bolus
Study NCT06094140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1
Study NCT06094140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF
Description: 6mg by subcutaneous injection to be given on day 3 of each cycle.
Study NCT05365386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel C
Description: This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology.
Study NCT06441773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Rehabilitation
Description: An initial assessment is conducted upon admission to personalize the program. This includes:~Clinical examination Spirometry Maximum Inspiratory Pressure (PImax) measurement Multidimensional Dyspnea Profile questionnaire at end of TM6 Exercise Functional Testing Measurement of quadriceps strength and endurance Blood gases Educational interview and shared educational assessment London Chest Activity of Daily Living (LCADL) Tobacco and/or dietary consultation~The respiratory rehabilitation program, performed twice a week, includes:~Exercise training on an ergocycle and treadmill (30 minutes at ventilatory threshold for the ergocycle; 30 minutes at 60-80% walking speed for the treadmill; or dyspnea rated 4-6 on the Borg scale after endurance exercise) Quadriceps muscle strengthening Therapeutic education program Group gymnastics Smoking cessation assistance Socio-psychological and nutritional support
Study NCT05064761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra new dilution
Description: Treatment to improve appearance of cellulite.
Study NCT06566664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B Braun HNS 12 nerve stimulator
Description: Nerve stimulator that is traditionally used for nerve localization during block placements.
Study NCT06566664 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: B Braun HNS 12 nerve stimulator sham control
Description: Stimulator will be placed but will not be turned on.
Study NCT05350202 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT05592431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)
Description: ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).
Study NCT05592431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Oscillatory Ventilation (SLE6000;SLE)
Description: ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
Study NCT05744128 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Zirconium 89Zr crefmirlimab berdoxam
Description: Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.
Study NCT05060471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
Study NCT05361421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive targeting group
Description: Intensive lipid lowering therapy with LDL-cholesterol goal of \<55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.
Study NCT05361421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy group
Description: Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
Study NCT05508997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: respiratory parameters on mechanical ventilator (PEEP)
Description: The 3rd \& 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~1. Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~2. Secondary outcome.~   * Ventilation by PaCO2 value from ABGs.~  * Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~  * Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups.
Study NCT05508997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: respiratory parameters on mechanical ventilator (PEEP)
Description: The 3rd \& 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~1. Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~2. Secondary outcome.~   * Ventilation by PaCO2 value from ABGs.~  * Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~  * Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups.
Study NCT04979520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
Study NCT05936268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for injection
Description: 150 mg/1ml/bottle
Study NCT05936268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5mg/table
Study NCT05565482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work Chat: An Interactive Virtual Workday
Description: Study participants will receive Standard Transition Services plus Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
Study NCT05825417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selexipag
Description: If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
Study NCT05825417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
Study NCT05825417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioMEMS pulmonary artery pressure monitor
Description: Implantation and remote monitoring established with patient initiated daily readings
Study NCT05825417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Confirm Rx
Description: Implantation and remote monitoring established with automated daily readings / downloads
Study NCT06383884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Description: Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day cycle as a fixed dose regimen of 5.6 mg/kg Q3W.
Study NCT05450783 — intervention group
Intervention type: OTHER
Intervention: Biocollection
Description: serum
Study NCT05974605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MM+HighC
Description: In this intervention, participants will be trained on a available mindfulness meditation app, followed by a working memory updating game, developed by Dr. Chandramallika Basak. This game requires high degree of attentional control (Unpredictable Bird Watch), also known as High-C. The app and the game are delivered through an Android tablet for this home-based training.
Study NCT06466499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention group
Description: Is described in arm
Study NCT04968587 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sustained Low-Efficiency Dialysis
Description: All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate
Study NCT06560840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
Study NCT05214794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nemolizumab
Description: nemolizumab will be administered subcutaneous injection
Study NCT05547048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: Decision aid for PrEP tailored for justice-involved women with opioid use disorder
Study NCT05547048 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Athena strategy
Description: eHealth for integrated PrEP/medications for opioid use disorder + decision aid
Study NCT06228742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral leg immobilization
Description: Participants will have one leg immobilized using a rigid knee brace. Participants will be expected to keep the knee brace on for 5 days and remain non-weight bearing on the immobilized leg. Participants will use crutches to remain non-weight bearing on the immobilized leg.
Study NCT06228742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contralateral active leg
Description: One leg will remain non-immobilized and active during the study. Participants will use this leg to walk with crutches.
Study NCT04699799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Present odors to participants while recording brain activity
Description: Present odors to participants while recording brain activity
Study NCT06560281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Minder Therapy (MoMT)
Description: Motion Minder Therapy (MoMT) total duration is 1 hour a day, 5 days a week for 4 weeks. The treatment is a carefully planned sequence of exercises intended to help children with spastic hemiplegic cerebral palsy develop their fine motor abilities. Activities includes Sticker Sorting, Beads on Parade, Pegboard Activities, Sensory Bins, Sculpture Building, Finger Painting \& Drawing with Different Tools, Musical Instrument Play. Smartwatches that have tactile sensations and auditory indications are used strategically during certain tasks to enhance proprioception and give real-time feedback, making the rehabilitation process vibrant and interesting.
Study NCT06269679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CBCT
Description: Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF.
Study NCT05766670 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin Hydrochloride
Description: The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
Study NCT05766670 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gentamicin
Description: The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
Study NCT05766670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Intramedullary Nail
Description: Standard Intramedullary Nail
Study NCT06251908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rewritalize
Description: REWR is conceptualised as a hybrid between an art group and a group therapy intervention. It is structured as a progressive participatory art group program led by a conductor-tandem: the primary conductor, a professional writer with extensive teaching experience, is supplemented by a co-conductor with clinical expertise who participates in the group activities together with the other participants. The conductor-tandem secure high artistic standards while also ensuring psychological safety. A close collaboration between the two is necessary and both participate in a 30-hour preparatory course and are supervised during the course of the intervention.~The writing course consists in 15 sessions of 3 hours per session. At each session participants are introduced to literary texts that work as prompts for the writing exercises, which last 5-15 min. After each text is read out loud, the participants engage in a reflective discussion about the text.
Study NCT06251908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard mental health care
Description: F-ACT is a community-based treatment model that provides multidisciplinary, flexible, and assertive outpatient treatment to patients with severe mental illness. OPUS is a nationally implemented 2-year-long early intervention for people with first-episode psychosis. OPUS is a multidisciplinary assertive community treatment model and offer psychoeducation, social skills training, relapse prevention and family involvement, including possibility for treatment participation in psychoeducational multifamily groups.~In F-ACT and OPUS a primary staff member is in regular contact with the patient and responsible for coordinating the treatment elements. The treatment is individual and contingent upon patients' needs.
Study NCT06251908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard mental health care
Description: F-ACT is a community-based treatment model that provides multidisciplinary, flexible, and assertive outpatient treatment to patients with severe mental illness. OPUS is a nationally implemented 2-year-long early intervention for people with first-episode psychosis. OPUS is a multidisciplinary assertive community treatment model and offer psychoeducation, social skills training, relapse prevention and family involvement, including possibility for treatment participation in psychoeducational multifamily groups.~In F-ACT and OPUS a primary staff member is in regular contact with the patient and responsible for coordinating the treatment elements. The treatment is individual and contingent upon patients' needs.
Study NCT06576908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperSight Imaging
Description: Subjects receive both HyperSight imaging and conventional imaging, on their first day of radiation treatment, on their second day of treatment, and on their last day of treatment.
Study NCT02178618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deployment of Partially covered biliary self expandable metal stent
Study NCT02178618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deployment of uncovered biliary self expandable metal stent
Study NCT05423158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: d-Coaching
Description: MOVN mobile app: Each participant will be assigned a secure login account that does not include personal information for research only. Participants will be trained on how to access and use the MOVN private social network group.~Annie text messaging: Participants will be registered in the Annie VA text messaging program to receive tailored, interactive push messages with a combination of 1 and 2-way tailored messages on goals, barriers, self-management, etc. (based on data collected in real-time from the Fitbit and barriers identified at baseline).~Fitbit wearable device \& mobile app: The intervention group will be instructed to use the Fitbit for step counts and maximizing the Fitbit mobile app/desktop platform to track all PA, sharing one's Fitbit profile with others (optional leaderboard), and use of all available features.
Study NCT04912557 — intervention group
Intervention type: OTHER
Intervention: postoperative pain assess
Description: numerical pain scale and Metameric levels of cold insensitivity
Study NCT05457244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-port robotic surgery
Description: Colorectal surgery using the da Vinci SP System will be performed via the umbilicus, McBurney's site or the reverse McBurney's site depending on the sites of lesion. All of these patients will undergo a standard minimally invasive resection in the same fashion as would be carried out with multiport laparoscopic or robotic surgery.
Study NCT04816526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Descartes 08
Description: Car T-cells
Study NCT06359002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYON4413
Description: BYON4413 will be administered by IV infusion.
Study NCT05047094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study NCT05047094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
Study NCT05767450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Vivomixx®
Description: The correct number of Vivomixx® sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
Study NCT05767450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The correct number of Placebo sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
Study NCT06254599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-3505 Capsules
Description: A third-generation ALK tyrosine kinase inhibitor
Study NCT06254599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib Capsules
Description: An oral ALK tyrosine kinase inhibitor
Study NCT05574634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet based adaptive multimodal attention practice program
Description: An adaptive at-home tablet-based program that includes variants of the Flanker Task, the Stroop Task, and a Visual Tracking Task. Each session of practice will include up to ten minutes with each of these task types, and the tasks will increase in difficulty in a way that further taxes attention (such as through more distractors or more incongruent trials) as participant performance improves.
Study NCT05574634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet based adaptive criterion task practice program
Description: An adaptive, at-home tablet-based variant of the criterion task, that is, the selective attention/distraction task used during the scanning portion of the human participant portions of the study, that takes up to 25 minutes to complete each session.